open access
Artificial intelligence and chimeric antigen receptor T-cell therapy
Affiliations- Department of Hematology and Bone Marrow Transplantation; Poznań University of Medical Sciences, 84 Szamarzewskiego str, 60-569 Poznań, Poland
- School of Biological Sciences, University of Manchester, Manchester, United Kingdom
open access
Abstract
Therapy with the use of chimeric antigen receptor T-cell (CAR T-cells) is one of the most modern medical technologies in hemato-oncology, using, thanks to the advances in molecular biology, natural anti-cancer immune mechanisms. Nowadays, it is an extremely effective complement to conventional treatment and hematopoietic cell transplantation. Ongoing clinical trials show the enormous potential of this treatment beyond hemato-oncology. We discuss in this paper the potential use of Artificial intelligence (AI) in this setting. AI has been at the cutting edge of science in recent years. It has spread from computer science to areas like medicine, economics, finance and business. The use of and research into AI in medicine have become prominent due to its versatility and capabilities.
Abstract
Therapy with the use of chimeric antigen receptor T-cell (CAR T-cells) is one of the most modern medical technologies in hemato-oncology, using, thanks to the advances in molecular biology, natural anti-cancer immune mechanisms. Nowadays, it is an extremely effective complement to conventional treatment and hematopoietic cell transplantation. Ongoing clinical trials show the enormous potential of this treatment beyond hemato-oncology. We discuss in this paper the potential use of Artificial intelligence (AI) in this setting. AI has been at the cutting edge of science in recent years. It has spread from computer science to areas like medicine, economics, finance and business. The use of and research into AI in medicine have become prominent due to its versatility and capabilities.
Keywords
artificial intelligence, machine learning, CAR T-cell therapy
About this articleTitle
Artificial intelligence and chimeric antigen receptor T-cell therapy
Journal
Issue
Article type
Review article
Pages
176-179
Published online
2022-05-25
Page views
2321
Article views/downloads
259
DOI
10.5603/AHP.a2022.0019
Bibliographic record
Acta Haematol Pol 2022;53(3):176-179.
Keywords
artificial intelligence
machine learning
CAR T-cell therapy
Authors
Lidia Gil
Maksymilian Grajek
References (16)- Erickson BJ, Korfiatis P, Akkus Z, et al. Machine learning for medical imaging. Radiographics. 2017; 37(2): 505–515.
- Zhou ZH. Machine learning. Springer, Singapore 2021.
- Jonsson A. Deep reinforcement learning in medicine. Kidney Dis (Basel). 2019; 5(1): 18–22.
- Zhang Z. written on behalf of AME Big-Data Clinical Trial Collaborative Group. Reinforcement learning in clinical medicine: a method to optimize dynamic treatment regime over time. Ann Transl Med. 2019; 7(14): 345.
- Rajpurkar P, Irvin J, Ball RL, et al. Deep learning for chest radiograph diagnosis: a retrospective comparison of the CheXNeXt algorithm to practicing radiologists. PLoS Med. 2018; 15(11): e1002686.
- Nicholls HL, John CR, Watson DS, et al. Reaching the end-game for GWAS: machine learning approaches for the prioritization of complex disease loci. Front Genet. 2020; 11: 350.
- Saria S, Henry K, Soleimani H, et al. Lead time and accuracy of trews, a machine learning-based sepsis alert. Critical Care Medicine. 2021; 50(1): 717.
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439–448.
- Schuster SJ, Bishop M, Tam C, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1): 45–56.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531–2544.
- Munoz JL, Wang Y, Jain P, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382(14): 1331–1342.
- Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254): 839–852.
- Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8): 705–716.
- Gil L, Łojko-Dankowska A, Matuszak M, et al. CAR-T cell therapy — toxicity and its management. Acta Haematol Pol. 2020; 51(1): 6–10.
- Chomienne C, Sierra J, Einsele H, et al. EHA Guidance. The process of CAR-T cell therapy in Europe. HemaSphere. 2019; 3(4).
- Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33(3): 259–275.